《大行報告》瑞銀下調泰格醫藥(03347.HK)目標價至173.82元 評級「買入」
瑞銀發表報告,指泰格醫藥(03347.HK)應能受惠於國家藥監局對抗腫瘤藥更嚴格的新規定,相信海外業務能夠成為其新增長動力。該行維持對泰格醫藥「買入」評級,不過目標價由246.76元下調至173.82元。
瑞銀表示,泰格醫藥積壓訂單量強勁,相信能確保短至中期盈利增長,該公司已經有超過140個海外臨床研究項目,超過30個全球多中心臨床研究項目,相信隨著更多中國創新藥研發公司進軍海外,泰格醫藥海外業務有廣闊增長空間。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.